Group 1 PAH: Current Therapies

Group 4 CTEPH

Prostacyclin Pathway: Modulation by Available Agents

SERAPHIN: Primary End Point*

Prostacyclin Pathway: Modulation by Investigational Agents

CTEPH: Lung Tissue Samples Show Distal Arteriopathy

Recent/Ongoing Trials: Address Previously Unmet Needs

Use of Other PAH Therapies

PATENT-1: Hypotension

Angiogenesis and PDGF: Modulation by Tyrosine Kinase

Inhibitors

PATENT-1 and SERAPHIN at ESC

References

References (cont)

References (cont)

Abbreviations

Abbreviations (cont)